124 related articles for article (PubMed ID: 30358823)
1. Treatable causes of diarrhoea in patients on tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Lightowlers SV; Greef B; Eisen T; Matakidou A; Fife K; Cameron EA
Ann Oncol; 2019 Jan; 30(1):150-151. PubMed ID: 30358823
[No Abstract] [Full Text] [Related]
2. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
3. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
Roviello G; Generali D
Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
[No Abstract] [Full Text] [Related]
4. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Bukowski RM
Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
[No Abstract] [Full Text] [Related]
5. The role of tyrosine kinase inhibitors in the treatment of renal cell carcinoma with brain metastases.
Aytekin A; Ciltas A; Sahinli H; Benekli M
J BUON; 2016; 21(1):281-2. PubMed ID: 27061562
[No Abstract] [Full Text] [Related]
6. Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?
Yaman S; Bilgin B; Şendur MA; Hızal M; Akıncı MB; Yalçın B
Future Oncol; 2019 Mar; 15(9):925-927. PubMed ID: 30854890
[No Abstract] [Full Text] [Related]
7. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
[TBL] [Abstract][Full Text] [Related]
8. Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma.
Hsiao YW; Lin YC; Hui RC; Yang CH
J Clin Oncol; 2011 Apr; 29(12):e340-1. PubMed ID: 21263088
[No Abstract] [Full Text] [Related]
9. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus.
Cetin B; Coskun U; Yildiz R; Buyukberber S; Baykara M; Benekli M
J Oncol Pharm Pract; 2011 Sep; 17(3):274-8. PubMed ID: 20215482
[TBL] [Abstract][Full Text] [Related]
10. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
Bukowski RM
Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708
[No Abstract] [Full Text] [Related]
11. Pyoderma gangrenosum with the use of sunitinib.
Nadauld LD; Miller MB; Srinivas S
J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
[No Abstract] [Full Text] [Related]
12. Lower limbs erosions induced by sunitinib.
Kluger N; Chapelle A; Jacot W; Guillot B
Acta Derm Venereol; 2011 May; 91(3):360-1. PubMed ID: 21103845
[No Abstract] [Full Text] [Related]
13. Selected toxicities of targeted therapies: presentation and management.
Kollmannsberger C; Mitchell T
Semin Oncol; 2013 Aug; 40(4):499-510. PubMed ID: 23972714
[TBL] [Abstract][Full Text] [Related]
14. Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Bamias A
Eur Urol; 2009 Jun; 55(6):1439. PubMed ID: 18950935
[No Abstract] [Full Text] [Related]
15. Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients.
Yamamoto K; Shinomiya K; Ioroi T; Hirata S; Harada K; Suno M; Nishioka T; Kume M; Makimoto H; Nakagawa T; Hirano T; Bito T; Nishigori C; Miyake H; Fujisawa M; Hirai M
Target Oncol; 2016 Feb; 11(1):93-9. PubMed ID: 26300443
[TBL] [Abstract][Full Text] [Related]
16. [First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO].
Rexer H; Steiner T; Grünwald V
Urologe A; 2017 Apr; 56(4):509-511. PubMed ID: 28251253
[No Abstract] [Full Text] [Related]
17. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib improves clinical outcomes in renal cancer.
Das M
Lancet Oncol; 2017 Jan; 18(1):e2. PubMed ID: 27890466
[No Abstract] [Full Text] [Related]
19. Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors?
Bamias A; Lainakis G; Manios E; Koroboki E; Karadimou A; Zakopoulos N; Dimopoulos MA
J Clin Oncol; 2009 May; 27(15):2567-9; author reply 2569-70. PubMed ID: 19332708
[No Abstract] [Full Text] [Related]
20. Novel tyrosine kinase inhibitors for renal cell carcinoma.
Dorff TB; Pal SK; Quinn DI
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):67-73. PubMed ID: 24308791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
